Published in Ann Intern Med on October 01, 1996
Cyclophosphamide and Fludarabine to Treat Lupus Nephritis | NCT00001676
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 6.51
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis (2005) 2.48
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis (2010) 2.09
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) (2009) 1.48
Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol (2007) 1.39
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.33
Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol (2003) 1.16
Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci Transl Med (2011) 1.11
Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. Pediatr Nephrol (2008) 1.07
B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol (2012) 1.05
A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol (2009) 1.03
Lupus nephritis: an overview of recent findings. Autoimmune Dis (2012) 1.00
Immune and inflammatory role in renal disease. Compr Physiol (2013) 0.97
Lupus nephritis: current update. Arthritis Res Ther (2011) 0.97
Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol (2011) 0.96
High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum (2010) 0.94
EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis (2004) 0.94
New therapies for systemic lupus erythematosus. Clin Exp Immunol (2005) 0.92
Diagnosis and treatment of lupus nephritis flares--an update. Nat Rev Nephrol (2012) 0.92
Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther (2012) 0.87
Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis (2003) 0.87
The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol (2010) 0.87
[Systemic lupus erythematosus--activity and outcome]. Z Rheumatol (2006) 0.87
Understanding lupus nephritis: diagnosis, management, and treatment options. Int J Womens Health (2012) 0.85
Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? Pediatr Nephrol (2004) 0.85
Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? Pediatr Nephrol (2007) 0.84
Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol (2010) 0.81
Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. Clin J Am Soc Nephrol (2014) 0.81
Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics (2013) 0.81
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis (2011) 0.81
Nonmalignant diseases and treatments associated with primary ovarian failure: an expanded role for fertility preservation. J Womens Health (Larchmt) (2011) 0.81
Intravenous cyclophosphamide--resistant systemic lupus erythematosus in Arizona. Pediatr Nephrol (2004) 0.80
Unexpected recovery from longterm renal failure in severe diffuse proliferative lupus nephritis. BMC Nephrol (2012) 0.80
Belimumab in systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2012) 0.80
Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. Int J Rheumatol (2013) 0.80
Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol (2010) 0.79
Aspergillus-associated cerebral aneurysm successfully treated by endovascular and surgical intervention with voriconazole in lupus nephritis patient. J Korean Med Sci (2012) 0.79
Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy. Clin Rheumatol (2005) 0.79
Mycophenolate mofetil in the treatment of lupus nephritis. Biologics (2008) 0.79
The treatment of systemic lupus proliferative nephritis. Pediatr Nephrol (2012) 0.79
Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. Rheumatol Int (2011) 0.78
Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther (2010) 0.78
Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis. Springerplus (2014) 0.78
Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis. Clin Rheumatol (2011) 0.78
A treatment algorithm for children with lupus nephritis to prevent developing renal failure. Int J Prev Med (2014) 0.77
Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care? Nephron Clin Pract (2010) 0.77
Outcome of reclassification of World Health Organization (WHO) class III under International Society of Nephrology-Renal Pathology Society (ISN-RPS) classification: retrospective observational study. Rheumatol Int (2011) 0.77
Acute glomerulonephritis. Postgrad Med J (2003) 0.77
The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis. Pediatr Nephrol (2009) 0.77
Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. Pediatr Nephrol (2005) 0.76
Systemic lupus erythematosus: a therapeutic challenge for the XXI century. Clin Rheumatol (2014) 0.76
Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2010) 0.76
Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis. Rheumatol Int (2007) 0.76
The outcome of proliferative lupus nephritis with pulse cyclophosphamide therapy. Indian J Nephrol (2011) 0.76
Recent advances in the treatment of lupus nephritis. Clin Exp Nephrol (2011) 0.75
Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India. Indian J Nephrol (2013) 0.75
Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy. Indian J Ophthalmol (2015) 0.75
Long-term outcome in lupus nephritis. Ann Intern Med (2002) 0.75
Chapter 12: Lupus nephritis. Kidney Int Suppl (2011) (2012) 0.75
Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study. BMC Nephrol (2016) 0.75
Lupus Nephritis: A Different Disease in European Patients? Kidney Dis (Basel) (2015) 0.75
Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: a case-control study. BMC Womens Health (2011) 0.75
Efficacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class IV lupus nephritis. Int J Clin Exp Med (2015) 0.75
Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study. Clin Exp Nephrol (2015) 0.75
Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis. Clin Exp Nephrol (2012) 0.75
Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome). Clin Rheumatol (2006) 0.75
Strength-duration curves for repetitive stimulation of medullated nerve. J Physiol (1934) 15.94
The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol (1989) 13.32
Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature (2001) 10.96
Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med (1980) 5.80
Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA (2001) 5.54
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci U S A (1984) 5.15
A dust-obscured massive maximum-starburst galaxy at a redshift of 6.34. Nature (2013) 4.43
Strategies for reducing coronary risk factors in primary care: which is most cost effective? BMJ (1995) 4.36
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
The pathogenesis of autoimmunity in New Zealand black mice. Curr Top Microbiol Immunol (1974) 3.98
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) (2002) 3.87
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells. J Exp Med (1975) 3.70
Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science (1982) 3.67
Asthma severity and adequacy of management in accident and emergency departments in France: a prospective study. Lancet (2001) 3.52
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int (1984) 3.10
Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol (1978) 3.07
Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J Immunol (1991) 3.04
X-linked B-lymphocyte immune defect in CBA/N mice. II. Studies of the mechanisms underlying the immune defect. J Exp Med (1975) 3.03
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
The genetics of the immune response to a synthetic double-stranded RNA in a mutant CBA mouse strain. J Immunol (1973) 3.00
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med (1992) 2.96
Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1978) 2.94
Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol (1980) 2.89
Heatstroke in well-wrapped infants. Lancet (1979) 2.81
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
Decline in suppressor T cell function with age in female NZB mice. J Immunol (1974) 2.79
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med (2001) 2.77
Three year follow up of patients with raised blood pressure identified at health checks in general practice. BMJ (1989) 2.74
Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med (1987) 2.71
Lifestyle advice in general practice: rates recalled by patients. BMJ (1992) 2.64
Costs and cost effectiveness of health checks conducted by nurses in primary care: the Oxcheck study. BMJ (1996) 2.58
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
Loss with age in NZB-W mice of thymic suppressor cells in the graft-vs-host reaction. J Immunol (1974) 2.45
Group A beta-hemolytic streptococci resistant to erythromycin and lincomycin. N Engl J Med (1968) 2.44
Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 2.38
Selective loss of suppressor cell function in New Zealand mice induced by NTA. J Immunol (1977) 2.38
Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med (1983) 2.38
Bilateral human fetal striatal transplantation in Huntington's disease. Neurology (2002) 2.34
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol (2005) 2.32
The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.31
Studies of immune functions of patients with systemic lupus erythematosus. I. Dysfunction of suppressor T-cell activity related to impaired generation of, rather than response to, suppressor cells. Arthritis Rheum (1979) 2.28
Methane-oxidizing microorganisms. Microbiol Rev (1981) 2.17
DNA-binding assay for detection of anti-DNA antibodies in NZB-NZW F1 mice. J Immunol (1969) 2.13
Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12
B-lymphocyte alloantigens associated with systemic lupus erythematosus. N Engl J Med (1978) 2.11
How should different life expectancies be valued? BMJ (1998) 2.10
Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med (1973) 2.10
Cardiovascular risk and attitudes to lifestyle: what do patients think? BMJ (1993) 2.07
Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus. J Clin Invest (1980) 2.06
Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med (1993) 2.05
Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med (1981) 2.05
Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE. Arthritis Rheum (1977) 2.03
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) (2007) 2.02
Modelling different strategies to prevent coronary heart disease in primary care. J Clin Epidemiol (1994) 2.02
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med (1993) 1.99
Factors affecting response to an invitation to attend for a health check. J Epidemiol Community Health (1993) 1.98
Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis (2011) 1.97
Desire for the body normal: body image and discrepancies between self reported and measured height and weight in a British population. J Epidemiol Community Health (1996) 1.96
Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet (1998) 1.95
Endomysial antibody: is it the best screening test for coeliac disease? Gut (1992) 1.93
Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med (1992) 1.90
Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int (1994) 1.88
Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J (1999) 1.87
Studies of immune functions of patients with systemic lupus erythematosus. Complement-dependent immunoglobulin M anti-thymus-derived cell antibodies preferentially inactivate suppressor cells. J Clin Invest (1979) 1.87
Effect of murine cytomegalovirus on the in vitro responses of T and B cells to mitogens. J Immunol (1976) 1.84
Isolation and characterisation of a bipotential haematopoietic cell line. Nature (1979) 1.80
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab (1996) 1.80
Multicentric reticulohistiocytosis: case report with immunohistochemical analysis and literature review. Arthritis Rheum (2000) 1.80
Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr (1996) 1.78